QRxPharma is a clinical stage specialty pharmaceutical company focused on developing and commercialising therapies to treat disorders of the central nervous system. Its lead products comprise a patented combination of existing drugs, with a well defined path to regulatory approval and sales. QRxPharma’s most advanced asset is a “dual opioid” drug for the treatment of moderate to severe pain.

QRx had an IPO in May 2007.